Novel Therapeutic Approaches for the Management of Diebetic Foot Ulceration

描述（由申请人提供）：糖尿病足溃疡（DFU）和相关的愈合受损，是一个严重影响糖尿病患者生活质量的主要问题，导致住院时间延长，仅在美国每年就有超过70,000例下肢截肢。然而，临床上对糖尿病创面愈合受损的病理生理分子机制的基础研究很少，阻碍了有效治疗方法的发展。当前应用的主要目的是在生物工程、基础研究和转化研究的研究人员之间建立合作，最终开发出新的生物材料，改善DFU的愈合。为此，来自威斯研究所和哈佛大学工程与应用科学学院的两名研究人员将参与其中。Mooney和Shih博士)，在开发新型生物材料方面拥有丰富的经验，贝斯以色列女执事医疗中心的两位研究人员(dr。Veves和LoGerfo)在糖尿病伤口愈合方面有着丰富的研究经验。新的生物材料，可以释放的物质，在PIs实验室的研究表明，改善伤口愈合，如神经肽，PTP1B抑制剂，生长因子和内皮祖细胞，将构建将由博士构建。Mooney和Shih博士的研究成果将在动物模型上进行测试。维夫斯和罗格福的实验室。该合作有潜力创建一个独特的，高功能和协同的研究团队，其专业知识涵盖了开发新生物材料所需的整个领域，并将专门专注于改善糖尿病伤口愈合。我们坚信并希望这次合作将导致DFU治疗的新治疗方法的发展，这些方法将在未来5到10年内临床可用。

DESCRIPTION (provided by applicant): Diabetic foot ulceration (DFU) and associated impairedhealing, is a major problem that significantly impairs the quality of life of diabetic patients, leading to prolonged hospitalization and resulting to more than 70,000 lower extremity amputations per year in the USA alone. However, there has been very little clinically driven basic research into the molecular mechanisms of the pathophysiology of impaired wound healing in diabetes, hampering the development of effective treatments. The main aim of the current application is to establish collaboration between investigators from bioengineering, basic and translational research that will eventually lead to the development of new biomaterials that will improve DFU healing. To this end, it will involve two investigators from the Wyss Institute and Harvard School of Engineering and Applied Sciences (Drs. Mooney and Shih), with extensive experience on developing new biomaterials and two investigators from the Beth Israel Deaconess Medical Center (Drs. Veves and LoGerfo) with extensive research experience in diabetic wound healing. The new biomaterials that can release substances that studies in the PIs laboratory have shown to improve wound healing, such as neuropeptides, PTP1B inhibitors, growth factors and endothelial progenitor cells, will be constructed will be constructed by the Drs. Mooney and Shih, and will be tested on animal models that have been developed by Drs. Veves' and LoGerfo's laboratory. This collaboratoryoration has the potential to create a unique, highly functional and synergistic investigative team with expertise that cover the whole range of fields that is required for the development of new biomaterials and will exclusively focus in improving diabetic- wound healing. It is our strong belief and hope that this collaboration will lead to the development of new therapeutic approaches for the treatment of DFU that will be clinically available over the next five to ten years. PUBLIC HEALTH RELEVANCE: The current application aims to develop new therapeutic approaches for a major clinical program, namely the management of diabetic foot ulcerations. Successful completion of this project may have a significant impact on the current clinical practice.